Overview

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The Phase Ia, open-label, multicenter study will consist of a single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of an intravitreal (ITV) injection of FCFD4514S in patients with Geographic Atrophy (GA).
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.